ARTL

1.3904.14%
AY

Andrew Yates

Senior VP & Chief Scientific Officer

Dr. Andrew Yates, also known as Andy, Ph.D., is Senior VP & Chief Scientific Officer of Artelo Biosciences, Inc. from 2021 and had been its Member of Scientific Advisor Board. Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR, FORXIGA and KEYTRUDA. Dr. Yates held key roles within the medical affairs, commercial, business development and strategy functions for AstraZeneca’s in-line and development portfolio. Dr. Yates has been extensively involved in the life-cycle management of key multi-billion dollar products leading to the funding and initiation of significant development programmes. Whilst in business development Dr. Yates led evaluations and transactions that resulted in multiple collaborative agreements with academia, biotechnology and peer pharma. Dr. Yates is a UK registered pharmacist who received PhD in cannabinoid medicinal chemistry from the University of Nottingham.

Positions